Genprex, Inc. Common Stock
Symbol: GNPX (NASDAQ)
0.21
▼ (-0.93%) -0.002
Company Description:
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Key Stats
- Today's Open: $0.2161
- Today's High: $0.227
- Today's Low: $0.208
- Today's Volume: 1.09M
- Yesterday Close: $0.216
- Yesterday High: $0.2256
- Yesterday Low: $0.2132
- Yesterday Volume: 1.34M
- Last Min Volume: 10
- Last Min High: $0.214
- Last Min Low: $0.214
- Last Min VWAP: $0.214
Company Profile
- Name: Genprex, Inc. Common Stock
- Website: https://www.genprex.com
- Listed Date: 2018-03-29
- Location: AUSTIN, TX
- Market Status: Active
- CIK Number: 0001595248
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $7.10M
- Round Lot: 100
- Outstanding Shares: 33.47M
- Asset Type: CS
RECENT FILINGS FOR GNPX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-15 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-05 | RW | View |
| 2025-08-04 | DEFA14A | View |
| 2025-08-04 | 8-K | View |
| 2025-07-16 | ARS | View |
| 2025-07-16 | DEF 14A | View |
| 2025-07-03 | PRE 14A | View |
| 2025-07-01 | 4 | View |
| 2025-07-01 | 4 | View |
| 2025-06-24 | 8-K | View |
| 2025-06-23 | 8-K | View |
| 2025-06-17 | EFFECT | View |
| 2025-06-17 | 424B3 | View |
| 2025-06-16 | CORRESP | View |
| 2025-06-16 | UPLOAD | View |
| 2025-06-11 | S-1 | View |
| 2025-06-11 | 8-K | View |
| 2025-06-09 | 8-K | View |
| 2025-05-14 | S-1 | View |
Latest News on GNPX